Oncolytics Biotech Inc (ONCY) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.77 (+0.10%), Market cap $0.11B, 52-week low–high $0.33 ~ $1.42.
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal ("GI") tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Financial statements, price targets, institutional (13F) holdings and related news for Oncolytics Biotech Inc are updated in real time on BlackAll Trade.
Oncolytics Biotech Inc trades at $0.77 (+0.10%). Real-time quotes and charts are available on BlackAll Trade.
Oncolytics Biotech Inc has a market cap of about $0.11B.
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenous